home / About us / Research Store / Latest reports / Services / NEWS & MEDIA / contact us

Reports

Ideas That Generate Results

Reports by Industry
Reports by Company
Global Antibody Drug Conjugate Drug Sales, Pipeline Analysis (By Phase, Linker, Technology, and Indication) & Market Forecast to 2023

Global Antibody Drug Conjugate Drug Sales, Pipeline Analysis (By Phase, Linker, Technology, and Indication) & Market Forecast to 2023

Format :  Adobe Reader (PDF) Upto 24 hour delivery
Publish Date : Aug, 2018| No. of Pages : 110

Share |
 
Please make your selection :
Electronic Access - Single User License
US$ 2000.00
CD-ROM Mail Delivery
US$ 2400.00
Hard Copy Mail Delivery
US$ 2400.00
Electronic Access - Multi-User License
US$ 3000.00
1. Analyst View
 
2. Research Methodology
 
3. Antibody Drug Conjugate (ADC) - An Introduction
 
4. Global Antibody Drug Conjugates Market Outlook to 2023
 
5. Commercialized Antibody Drug Conjugates
    5.1 ADCETRIS 
    5.2 Kadcyla
    5.3 Mylotarg
    5.4 Besponsa
 
6. Antibody Drug Conjugates Pipeline Analysis
    6.1 By Companies
          6.1.1 By Clinical Phase
          6.1.2 By Indication
          6.1.3 By Drug
          6.1.4 By Type of Linker
          6.1.5 By Technology
    6.2 By Research Organizations
          6.2.1 By Phase
          6.2.2 By Indication
          6.2.3 By Drug
          6.2.4 By Type of Linker
          6.2.5 By Technology
 
7. Drivers and Challenges
    7.1 Drivers
          7.1.1 Rising Global Cancer Epidemics
          7.1.2 Advances in Linking Technologies Re-Instills Hope in ADC
          7.1.3 Efforts towards Patent Protection to Drive ADC Market
          7.1.4 Increasing Demand for Antibody Drug Conjugates
    7.2 Challenges
          7.2.1 Production Hurdles and Cost
          7.2.2 Inadequacy of Experienced Manufacturers
          7.2.3 Regulatory Challenges
 
8. Major Potential Antibody Drug Conjugates in Pipeline
    8.1 By Companies
          8.1.1 Glembatumumab Vedotin Therapeutics/CDX-011 - Celldex
          8.1.2 Coltuximab Ravtansine/SAR3419 - ImmunoGen Inc.
          8.1.3 Indatuximab Ravtansine/BT-062 – Biotest AG
          8.1.4 Anti-PSMA ADC Therapeutic - Progenics Pharmaceuticals
          8.1.5 Polatuzumab Vedotin/RG7596 - F. Hoffman-La Roche Ltd.
          8.1.6 DMUC-4064A/RG7882 - F. Hoffman-La Roche Ltd.
          8.1.7 Mirvetuximab Soravtansine/IMGN853 - ImmunoGen Inc.
    8.2 By Research Organizations
          8.2.1 SGM-101 - SurgiMab in Collaboration with Center for Human Drug Research, Netherlands
          8.2.2 MOC31-PE - Creative Biolabs in Collaboration with Oslo University Hospital
 
9. Trends and Developments
    9.1 ADC at the Forefront of Treating Hematological Malignancies
    9.2 ADCs Proving Advantageous for Breast Cancer Patients
 
10. Strategic Alliances in the Global Antibody Drug Conjugates Industry
 
11. Competitive Assessment
      11.1 Seattle Genetics, Inc.
      11.2 F. Hoffman-La Roche Ltd.
      11.3 Pfizer Inc.
      11.4 ImmunoGen, Inc.
      11.5 Bayer AG
      11.6 Takeda Pharmaceutical Company Limited
      11.7 Immunomedics, Inc.
      11.8 Oxford BioTherapeutics
      11.9 Concortis Biotherapeutics
      11.10 NBE-Therapeutics
Not able to find data you are looking for? Ask our Research Analyst.

media citation

get in touch

Please fill-in the information below.

Not readable? Change text.